COMPOSITIONS OF GINSENOSIDE RG3 AND GINSENOSIDE RG5 AND THEIR PHARMACEUTICAL USES INCLUDING ANTI-TUMOR EFFECTS

Abstract

In one aspect, a composition of ginsenoside Rg3 and ginsenoside Rg5 and a preparation method thereof, as well as its application in manufacturing drugs, foods and health products for boosting immunity, enhancing anti-tumor effects, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effects. The composition has advantages in rapid action, less toxicity and side effects and is suitable for long-term use. In another aspect, a safe, highly efficient and stable drug, food or health product which can be obtained by a simple preparation process suitable for industrial production and which can be easily scaled up. In yet another aspect, a new type of components and production process for manufacturing drugs, foods and health products for boosting immunity, enhancing anti-tumor effect, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effect.

Claims

1. A method for preparing a composition comprising ginsenoside Rg3 and ginsenoside Rg5, the method comprising the following steps: 1)Mixing panax ginseng with Chinese medicinal materials; 2) Decocting the mixture obtained from step 1) with water several times, and collecting and combining the decoction fluid; 3) Adding a clarifying agent to the decoction fluid obtained from step 2), mixing well, allowing to stand and filtering; 4) Drying the filtrate obtained from step 3) to obtain a dried substance; 5) Adding ethanol aqueous solution to the dried substance obtained from step 4), heating to dissolve, filtering, and subjecting to the low-temperature crystallization process; and 6) Drying the crystals obtained from step 5), Wherein, the Chinese medicinal materials are selected from the group consisting of one or more of the following medicines: mulberry, fried aurantii fructus, paeoniae radix alba, citri sarcodactylis fructus, nelumbinis rhizomatis nodus, fried aurantii fructus immaturus, gingko nut, diospyros kaki calyx, aconitum kusnezoffii leaf, lotus seedpod, ailanthi cortex, Chinese arborvitae twig, punica granatum peel, cornus officinalis, gallnut, rhizoma bletillae, white aconite, fructus toosendan, trichosanthis radix, codonopsis pilosula, purple iris, artemisia annua, chinese honeylocust spine, fructus foeniculi, kochia scoparia fruit, peach kernel, mume fructus, herba epimedii, chicken's gizzard-membrane, root of eichmannia, dioscorea oppositifolia, gentiana macrophylla root, adenophora stricta root, pyrrosia lingua, salvia miltiorrhiza, pharbitidis semen, rigonellae semen, lablab purpureus seed, fructus perillae, rhizoma pinelliae preparata, coptis chinensis rhizome, cullen corylifolium fruit, phellodendri chinensis cortex, rhizoma corydalis, canarii fructus, eclipta prostrata, papaya, portulacae herba, citrus medica, achyranthes bidentata, rubus chingii, fallopia multiflora, fraxini cortex, trachycarpus fortunei, nelumbinis semen, agrimonia pilosa herb, green plum, alumen, papaveris pericarpium, terminalia chebula, rosa laevigata, sanguisorba officinalis, prunus dulcis, citrus reticulata pericarp, gardenia jasminoides, ligustri lucidi fructus, rehmannia glutinosa processed root tuber, scutellariae radix, reed rhizome, astragali radix, curcumae rhizoma, mori cortex, ophiopogonis radix, arecae semen, raw frankincense, spatholobi caulis, atractylodis macrocephalae rhizoma, lycii cortex, angelica sinensis, prunus mume smoke treated unripe fruit, hordeum vulgare sprout, eriobotrya japonica leaf, platycladus orientalis seed, cinnamon, asparagi radix, raw myrrh, platycodonis radix, perotis indica, processed radix aconiti lateralis, chrysanthemi flos, aucklandiae radix, radix stemonae, sparganii rhizoma, eucommiae cortex, citrus reticulata fruit peel, rheum officinale, pericarpium arecae, gastrodia elata, pseudostellariae radix, paeonia rubra root, flos inulae, prunella vulgaris, cuscuta chinensis seed, drynaria fortunei, curcumae radix, arisaema cum bile, radix stemonae, taraxacum mongolicum herb, licorice, cimicifugae rhizoma, corydalis bungeana, rubia cordifolia, linderae radix, acanthopanax gracilistylus root bark, aconiti radix, lichee exocarp, emblic leafflower fruit, belamcandae rhizoma, folium isatidis, euodiae fructus, carthami flos, cyperi rhizoma, schisandra chinensis, ziziphus jujuba seed, crataegi fructus and radix lithospermi.

2. The method of claim 1, wherein the Chinese medicinal materials are selected from the group consisting of one or more of the following medicines: curcumae radix, arisaema cum bile, radix stemonae, chrysanthemi flos, aucklandiae radix, schisandra chinensis, sparganii rhizoma, atractylodis macrocephalae rhizoma, fructus phyllanthi fruit, pharbitidis semen, phellodendri chinensis cortex, cullen corylifolium fruit, lablab purpureus seed, prunus mume smoke treated unripe fruit, fructus perillae, salvia miltiorrhiza, pyrrosia lingua, dioscorea oppositifolia, root of eichmannia, gentiana macrophylla root, adenophora stricta root, coptis chinensis rhizome, rigonellae semen, rhizoma corydalis, green plum, eucommiae cortex, citrus reticulata fruit peel, ziziphus jujuba seed, gingko nut, punica granatum peel, peach kernel, rhizoma bletillae, cuscuta chinensis seed, crataegi fructus, paeoniae radix alba, Chinese arborvitae twig, pseudostellariae radix, paeonia rubra root, fructus foeniculi, artemisia annua, gallnut, trichosanthis radix, codonopsis pilosula, fructus toosendan, cornus officinalis, aurantii fructus immaturus, lotus seedpod, mulberry, chicken's gizzard-membrane, aurantii fructus, ailanthi cortex, aconitum kusnezoffii, michaelmas daisy, chinese honeylocust spine, kochia scoparia fruit, pinelliae rhizoma, rhei radix et rhizoma, Gastrodia elata, flos inulae and prunella vulgaris.

3. The method of claim 1, wherein the weight ratio of panax ginseng to the Chinese medicinal materials is 1:100 to 100:1, for example, 1:90-100, 1:45-55, 10:8-12, 45-55:1 or 90-100:1.

4. The method of claim 1, wherein the number of decoctions is 2-5 times, preferably 3 times.

5. The method of claim 1, wherein the weight of water used for each decoction is 2-100 times, preferably 2-80 times, the total weight of panax ginseng and the Chinese medicinal materials.

6. The method of claim 1, wherein each decoction time is 1-36 h, preferably 2-24 h.

7. The method of claim 1, wherein the temperature of each decoction is 90-100° C., preferably 95-100° C.

8. The method of claim 1, wherein the clarifying agent is the ZTC1+1 clarifying agent.

9. The method of claim 8, wherein the final concentration after the addition of the ZTC1+1 clarifying agent is 200-800 ppm.

10. The method of claim 1, wherein the period of standing is 4-48 h, preferably 4-24 h.

11. The method of claim 1, wherein the aqueous ethanol solution used for crystallization is 40-90% (V/V) aqueous ethanol solution.

12. A composition comprising ginsenoside Rg3 and ginsenoside Rg5 and prepared by a process as claimed in claim 1.

13. The composition of claim 12, wherein the percentage of the total weight of ginsenoside Rg3 and ginsenoside Rg5 to the composition is 1% to 100%, such as 98.0% to 100%.

14. A composition comprising the composition of claim 12 and an acceptable carrier in the industries of pharmaceutics or foods.

15. The composition of claim 14, wherein the weight ratio of the composition to the acceptable carrier in the industries of pharmaceutics or foods is 1:1 to 1:100.

16. The composition of claim 14, wherein the composition is in the form of tablets, capsules, pills, powder, granules, syrup, solution, emulsion, spray, aerosol, gel, cream, cataplasm, adhesive plaster or emplastrums, or in the form of foods, dairy products, confectionery, beverages, biscuits, tea leaves and related products, or wine.

17. The composition of claim 12 useful in the preparation of drug products for boosting immunity, enhancing anti-tumor effect, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effect.

18. A method for boosting immunity, enhancing anti-tumor effect, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effect, which comprises: administering an effective amount of the composition of claim 12 to an individual in need of boosting immunity, enhancing anti-tumor effect, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effect.

Description

DETAILED DESCRIPTION

[0054] The beneficial effects of the formulations described in the present invention are further described below using the specific embodiments. These exemplary embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be appreciated by those skilled in the art that the details and forms of the technical proposal of the present invention can be modified or substituted without departing from the formulation ideas and scope of use of the present invention. However, all these modifications and substitutions fall within the scope of protection of the present invention.

EXEMPLARY EMBODIMENTS 1-180

Preparation of a Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0055] The specific process route is as follows: decoct the mixture of panax ginseng and other raw materials with water three times, pool the water solution and concentrate the mixture to the concentration of crude drug/water of 1:5 (v/v), maintain the temperature at 60-80° C., add ZTC1+1-II clarifying agent (it can be purchased from Wuhan Zheng Tian Cheng Biological Science & Technology Co., Ltd.) to its final concentration of 500 ppm, stir evenly, allow to stand, filter, dry the filtrate, add ethanol solution to dissolve at 60° C., cool after filtration, separate the crystals in an ice water bath, collect the precipitate, and dry to obtain the finished product. The content of each component is determined by HPLC.

[0056] The panax ginseng is respectively weighed with various crude drugs according to the weights described in Table 1 and then mixed and extracted in accordance with the above process route and the parameters described in Table 2 for preparation. The test data of the obtained finished product are presented in Table 3.

TABLE-US-00001 TABLE 1 Raw Material Ratio and Finished Product Weight of Exemplary Embodiment 1-180 Weight Weight of Amount of Composition Other raw of panax other raw finished Serial No. materials ginseng (g) materials (g) products (g) 1 (or A) Curcumae 100 1 3.2 2 (or B) radix 100 10000 23.6 3 (or C) 100 5000 8.1 4 (or D) Arisaema cum 100 100 6.2 5 (or E) bile 100 10000 22.0 6 (or F) 100 5000 7.9 7 (or G) Radix 100 1 3.1 8 (or H) stemonae 100 10000 22.5 9 (or I) 100 5000 7.8 10 Chrysanthemi 100 1 2.8 11 flos 100 10000 19.3 12 100 5000 6.4 13 Aucklandiae 100 100 6.0 14 radix 100 10000 21.8 15 100 5000 7.7 16 Schisandra 100 1 3.3 17 chinensis 100 10000 22.9 18 100 5000 7.9 19 Sparganii 100 1 3.7 20 rhizoma 100 10000 22.9 21 100 5000 8.5 22 Atractylodis 100 100 6.6 23 macrocephalae 100 10000 21.9 24 rhizoma 100 5000 7.7 25 Phyllanthus 100 1 3.3 26 emblica 100 10000 22.5 27 100 5000 7.9 28 Pharbitidis 100 1 3.0 29 Semen 100 10000 23.1 30 100 5000 8.0 31 Phellodendri 100 100 6.4 32 chinensis 100 10000 23.4 33 cortex 100 5000 8.2 34 Cullen 100 1 3.2 35 corylifolium 100 10000 22.8 36 fruit 100 5000 8.3 37 Lablab 100 1 2.9 38 purpureus seed 100 10000 23.3 39 100 5000 7.7 40 Prunus mume 100 100 6.9 41 smoke treated 100 10000 22.8 42 unripe fruit 100 5000 8.3 43 Fructus perillae 100 1 3.8 44 100 10000 22.8 45 100 5000 8.2 46 Salvia 100 1 3.8 47 miltiorrhiza 100 10000 24.0 48 100 5000 9.3 49 Pyrrosia lingua 100 100 7.4 50 100 10000 22.0 51 100 5000 7.9 52 Dioscorea 100 1 4.5 53 oppositifolia 100 10000 24.9 54 100 5000 8.8 55 Dried rhizome 100 1 4.7 56 of rehmannia 100 10000 26.7 57 100 5000 10.3 58 Gentiana 100 100 6.1 59 macrophylla 100 10000 21.8 60 root 100 5000 8.3 61 Adenophora 100 1 4.2 62 stricta root 100 10000 25.6 63 100 5000 8.7 64 Coptis 100 1 3.7 65 chinensis 100 10000 25.0 66 rhizome 100 5000 9.3 67 Faenum 100 100 5.3 68 graecum 100 10000 18.6 69 100 5000 4.6 70 Rhizoma 100 1 3.9 71 corydalis 100 10000 24.8 72 100 5000 9.0 73 Prunus mume 100 1 3.6 74 100 10000 22.8 75 100 5000 7.3 76 Eucommiae 100 100 6.4 77 cortex 100 10000 21.2 78 100 5000 8.9 79 Citrus 100 1 4.2 80 reticulata 100 10000 23.6 81 fruit peel 100 5000 8.9 82 Ziziphus jujuba 100 1 4.5 83 seed 100 10000 25.9 84 100 5000 7.4 85 Ginkgo nut 100 100 6.7 86 100 10000 21.5 87 100 5000 6.4 88 Punica 100 1 1.7 89 granatum 100 10000 23.1 90 peel 100 5000 8.4 91 Peach kernel 100 1 4.9 92 100 10000 23.3 93 100 5000 8.8 94 Bletilla striata 100 100 6.0 95 100 10000 22.8 96 100 5000 7.7 97 Cuscuta 100 1 3.0 98 chinensis seed 100 10000 22.4 99 100 5000 7.7 100 Crataegus 100 1 3.2 101 pinnatifida 100 10000 23.1 102 100 5000 8.2 103 Paeoniae radix 100 100 6.3 104 alba 100 10000 22.9 105 100 5000 7.0 106 Platycladus 100 1 3.0 107 orientalis leaf 100 10000 22.7 108 100 5000 7.6 109 Pseudostellaria 100 1 3.4 110 heterophylla 100 10000 23.4 111 100 5000 8.2 112 Paeonia rubra 100 100 6.9 113 root 100 10000 22.4 114 100 5000 7.5 115 Foeniculum 100 1 3.6 116 vulgare dry 100 10000 22.0 117 fruit 100 5000 7.4 118 Artemisia 100 1 3.2 119 annua 100 10000 23.3 120 100 5000 8.4 121 Rhus spp. galls 100 100 6.0 122 100 10000 22.2 123 100 5000 7.8 124 Trichosanthes 100 1 3.2 125 spp. root 100 10000 22.5 126 100 5000 7.7 127 Codonopsis 100 1 3.3 128 pilosula 100 10000 23.9 129 100 5000 8.8 130 Toosendan 100 100 6.6 131 fructus 100 10000 22.6 132 100 5000 7.4 133 Corni fructus 100 1 3.6 134 100 10000 22.1 135 100 5000 7.2 136 Citrus 100 1 3.9 137 aurantium 100 10000 23.9 138 100 5000 8.1 139 Lotus seedpod 100 100 6.1 140 100 10000 22.1 141 100 5000 7.0 142 Mulberry 100 1 3.3 143 100 10000 22.7 144 100 5000 7.1 145 Chicken's 100 1 3.5 146 gizzard- 100 10000 23.0 147 membrane 100 5000 8.5 148 Aurantii 100 100 6.7 149 Fructus 100 10000 22.5 150 100 5000 7.5 151 Ailanthi cortex 100 1 3.2 152 100 10000 22.8 153 100 5000 7.3 154 Aconitum 100 1 3.9 155 kusnezoffii 100 10000 23.5 156 100 5000 8.3 157 Michaelmas 100 100 6.4 158 daisy 100 10000 22.6 159 100 5000 7.7 160 Chinese 100 1 3.1 161 honeylocust 100 10000 22.6 162 spine 100 5000 7.1 163 Kochia 100 1 3.7 164 scoparia 100 10000 23.3 165 fruit 100 5000 8.0 166 Pinellia ternata 100 100 6.4 167 100 10000 22.5 168 100 5000 7.5 169 Rheum 100 1 3.9 170 officinale 100 10000 22.5 171 100 5000 7.9 172 Gastrodia elata 100 1 3.1 173 100 10000 23.8 174 100 5000 8.0 175 Flos inulae 100 100 6.5 176 100 10000 22.9 177 100 5000 7.4 178 Prunella 100 1 3.7 179 vulgaris 100 10000 22.2 180 100 5000 7.0

TABLE-US-00002 TABLE 2 Sample Preparation Process Parameters for Exemplary Embodiment 1-180 Composition Amount of Standing Content of Amount of Serial No. water (ml) time (h) ethanol (%) ethanol (ml) 1 4000 8 50 200 2 400000 8 50 2000 3 250000 8 60 1000 4 8000 12 60 200 5 400000 12 70 2000 6 200000 12 70 1000 7 5000 24 80 200 8 500000 24 80 2000 9 250000 24 80 1000 10 4000 8 50 200 11 400000 8 50 2000 12 250000 8 60 1000 13 8000 12 60 200 14 400000 12 70 2000 15 200000 12 70 1000 16 5000 24 80 200 17 500000 24 80 2000 18 250000 24 80 1000 19 4000 8 50 200 20 400000 8 50 2000 21 250000 8 60 1000 22 8000 12 60 200 23 400000 12 70 2000 24 200000 12 70 1000 25 5000 24 80 200 26 500000 24 80 2000 27 250000 24 80 1000 28 4000 8 50 200 29 400000 8 50 2000 30 250000 8 60 1000 31 8000 12 60 200 32 400000 12 70 2000 33 200000 12 70 1000 34 5000 24 80 200 35 500000 24 80 2000 36 250000 24 80 1000 37 4000 8 50 200 38 400000 8 50 2000 39 250000 8 60 1000 40 8000 12 60 200 41 400000 12 70 2000 42 200000 12 70 1000 43 5000 24 80 200 44 500000 24 80 2000 45 250000 24 80 1000 46 4000 8 50 200 47 400000 8 50 2000 48 250000 8 60 1000 49 8000 12 60 200 50 400000 12 70 2000 51 200000 12 70 1000 52 5000 24 80 200 53 500000 24 80 2000 54 250000 24 80 1000 55 4000 8 50 200 56 400000 8 50 2000 57 250000 8 60 1000 58 8000 12 60 200 59 400000 12 70 2000 60 200000 12 70 1000 61 5000 24 80 200 62 500000 24 80 2000 63 250000 24 80 1000 64 4000 8 50 200 65 400000 8 50 2000 66 250000 8 60 1000 67 8000 12 60 200 68 400000 12 70 2000 69 200000 12 70 1000 70 5000 24 80 200 71 500000 24 80 2000 72 250000 24 80 1000 73 4000 8 50 200 74 400000 8 50 2000 75 250000 8 60 1000 76 8000 12 60 200 77 400000 12 70 2000 78 200000 12 70 1000 79 5000 24 80 200 80 500000 24 80 2000 81 250000 24 80 1000 82 4000 8 50 200 83 400000 8 50 2000 84 250000 8 60 1000 85 8000 12 60 200 86 400000 12 70 2000 87 200000 12 70 1000 88 5000 24 80 200 89 500000 24 80 2000 90 250000 24 80 1000 91 4000 8 50 200 92 400000 8 50 2000 93 250000 8 60 1000 94 8000 12 60 200 95 400000 12 70 2000 96 200000 12 70 1000 97 5000 24 80 200 98 500000 24 80 2000 99 250000 24 80 1000 100 4000 8 50 200 101 400000 8 50 2000 102 250000 8 60 1000 103 8000 12 60 200 104 400000 12 70 2000 105 200000 12 70 1000 106 5000 24 80 200 107 500000 24 80 2000 108 250000 24 80 1000 109 4000 8 50 200 110 400000 8 50 2000 111 250000 8 60 1000 112 8000 12 60 200 113 400000 12 70 2000 114 200000 12 70 1000 115 5000 24 80 200 116 500000 24 80 2000 117 250000 24 80 1000 118 4000 8 50 200 119 400000 8 50 2000 120 250000 8 60 1000 121 8000 12 60 200 122 400000 12 70 2000 123 200000 12 70 1000 124 5000 24 80 200 125 500000 24 80 2000 126 250000 24 80 1000 127 4000 8 50 200 128 400000 8 50 2000 129 250000 8 60 1000 130 8000 12 60 200 131 400000 12 70 2000 132 200000 12 70 1000 133 5000 24 80 200 134 500000 24 80 2000 135 250000 24 80 1000 136 4000 8 50 200 137 400000 8 50 2000 138 250000 8 60 1000 139 8000 12 60 200 140 400000 12 70 2000 141 200000 12 70 1000 142 5000 24 80 200 143 500000 24 80 2000 144 250000 24 80 1000 145 4000 8 50 200 146 400000 8 50 2000 147 250000 8 60 1000 148 8000 12 60 200 149 400000 12 70 2000 150 200000 12 70 1000 151 5000 24 80 200 152 500000 24 80 2000 153 250000 24 80 1000 154 4000 8 50 200 155 400000 8 50 2000 156 250000 8 60 1000 157 8000 12 60 200 158 400000 12 70 2000 159 200000 12 70 1000 160 5000 24 80 200 161 500000 24 80 2000 162 250000 24 80 1000 163 4000 8 50 200 164 400000 8 50 2000 165 250000 8 60 1000 166 8000 12 60 200 167 400000 12 70 2000 168 200000 12 70 1000 169 5000 24 80 200 170 500000 24 80 2000 171 250000 24 80 1000 172 4000 8 50 200 173 400000 8 50 2000 174 250000 8 60 1000 175 8000 12 60 200 176 400000 12 70 2000 177 200000 12 70 1000 178 5000 24 80 200 179 500000 24 80 2000 180 250000 24 80 1000

TABLE-US-00003 TABLE 3 Composition Contents of Exemplary Embodiment 1-180 Content of Rg3 Proportion of each component Composition and Rg5 in the in the composition (%) Serial No. composition s-Rg3 R-Rg3 Rg5 1 98.1% 1 98 1 2 2.2% 1 1 98 3 11.6% 98 1 1 4 98.0% 98 1 1 5 2.4% 1 98 1 6 10.7% 1 98 1 7 98.3% 1 1 98 8 2.3% 98 1 1 9 10.1% 1 1 98 10 98.2% 1 98 1 11 3.1% 1 1 98 12 11.8% 98 1 1 13 97.3% 97 2 1 14 3.3% 1 98 1 15 10.9% 1 98 1 16 98.1% 1 1 98 17 2.7% 98 1 1 18 10.0% 1 1 98 19 98.1% 2 96 2 20 2.7% 1 1 98 21 11.4% 98 1 1 22 98.6% 98 1 1 23 2.6% 1 98 1 24 10.4% 2 95 3 25 98.4% 1 1 98 26 3.2% 98 1 1 27 10.8% 1 1 98 28 97.9% 1 98 1 29 2.6% 1 1 98 30 11.8% 98 1 1 31 97.8% 98 1 1 32 2.4% 3 96 1 33 10.4% 1 98 1 34 98.9% 1 1 98 35 2.5% 98 1 1 36 10.7% 1 1 98 37 98.8% 1 98 1 38 2.5% 1 1 98 39 11.6% 98 1 1 40 98.3% 98 1 1 41 2.6% 2 97 1 42 10.8% 1 98 1 43 98.5% 1 1 98 44 2.4% 98 1 1 45 10.1% 1 1 98 46 98.4% 3 96 1 47 2.2% 1 1 98 48 11.4% 98 1 1 49 98.1% 97 1 2 50 2.5% 1 98 1 51 10.6% 1 98 1 52 98.6% 1 1 98 53 2.8% 98 1 1 54 10.6% 1 1 98 55 98.4% 1 98 1 56 2.8% 1 1 98 57 11.2% 96 1 3 58 98.3% 97 1 2 59 2.6% 1 98 1 60 10.7% 1 98 1 61 98.7% 1 1 98 62 2.4% 98 1 1 63 10.2% 1 1 98 64 98.6% 1 97 2 65 2.4% 1 1 98 66 11.4% 98 1 1 67 98.5% 98 1 1 68 2.7% 1 95 4 69 10.7% 1 98 1 70 98.5% 1 1 98 71 2.8% 98 1 1 72 10.8% 1 1 98 73 98.7% 2 93 5 74 2.5% 1 1 98 75 11.4% 98 1 1 76 98.6% 98 1 1 77 2.1% 1 97 2 78 10.8% 1 98 1 79 98.4% 1 1 98 80 2.6% 98 1 1 81 10.2% 1 1 98 82 98.3% 0 99 1 83 2.6% 1 1 98 84 11.5% 98 1 1 85 98.8% 98 1 1 86 2.4% 1 98 1 87 10.8% 5 94 1 88 98.5% 1 1 98 89 2.5% 98 1 1 90 11.2% 1 1 98 91 98.1% 1 98 1 92 2.6% 1 1 98 93 11.0% 98 1 1 94 98.4% 98 1 1 95 2.3% 1 97 2 96 10.4% 1 98 1 97 98.5% 1 1 98 98 2.3% 98 1 1 99 10.3% 1 1 98 100 98.5% 1 96 3 101 2.1% 1 1 98 102 11.3% 98 1 1 103 97.6% 98 1 1 104 2.4% 1 98 1 105 10.5% 1 98 1 106 97.8% 1 1 98 107 2.8% 97 1 2 108 10.3% 1 1 98 109 98.4% 1 98 1 110 3.8% 1 2 97 111 11.5% 98 1 1 112 98.5% 98 1 1 113 2.5% 1 98 1 114 10.4% 1 98 1 115 97.6% 1 1 98 116 2.8% 98 1 1 117 10.5% 1 1 98 118 97.5% 1 98 1 119 2.4% 2 2 96 120 11.3% 98 1 1 121 98.4% 98 1 1 122 2.5% 1 98 1 123 10.8% 1 98 1 124 98.5% 1 1 98 125 2.6% 98 1 1 126 10.5% 1 1 98 127 97.9% 1 96 3 128 2.5% 1 1 98 129 11.4% 98 1 1 130 98.8% 98 1 1 131 2.8% 1 98 1 132 10.5% 1 98 1 133 98.4% 1 1 98 134 2.5% 98 1 1 135 10.5% 1 1 98 136 98.5% 1 97 2 137 2.3% 1 1 98 138 11.7% 98 1 1 139 97.8% 98 1 1 140 2.8% 1 95 4 141 10.5% 1 98 1 142 98.3% 1 1 98 143 2.8% 98 1 1 144 10.4% 1 1 98 145 98.0% 1 98 1 146 2.6% 1 1 98 147 11.0% 98 1 1 148 98.1% 98 1 1 149 2.5% 1 98 1 150 10.8% 3 92 5 151 98.7% 1 1 98 152 2.2% 98 1 1 153 10.4% 1 1 98 154 98.8% 1 98 1 155 2.6% 1 1 98 156 11.7% 98 1 1 157 98.2% 98 1 1 158 2.4% 3 93 4 159 11.6% 1 98 1 160 98.8% 1 1 98 161 2.7% 96 3 1 162 10.1% 1 1 98 163 98.3% 1 98 1 164 2.5% 1 1 98 165 11.7% 98 1 1 166 98.8% 98 1 1 167 2.1% 1 92 7 168 10.2% 1 98 1 169 98.5% 1 1 98 170 2.3% 98 1 1 171 10.6% 1 1 98 172 97.1% 1 98 1 173 2.4% 1 1 98 174 11.8% 98 1 1 175 98.8% 98 1 1 176 2.7% 4 96 0 177 10.1% 2 97 1 178 98.9% 1 1 98 179 2.1% 93 1 6 180 10.5% 1 1 98

EXEMPLARY EMBODIMENTS 181-198

Preparation of the Composition of Ginsenoside Rg3 and Ginsenoside Rg5 and the Composition of Cyclodextrins

[0057] Take the composition of ginsenoside Rg3 and ginsenoside Rg5 prepared according to the process of Exemplary Embodiments 1-180 and prepare the composition at a weight ratio described in Table 4 and according to the following procedure: 1) directly add it to a cyclodextrin solution or a solution of cyclodextrin derivative; 2) directly add it to a cyclodextrin solution or a solution of cyclodextrin derivative and stirring thoroughly for 1-24 h; 3) directly add it to a cyclodextrin solution or a solution of cyclodextrin derivative and heating for 10-120 min; 4) directly add it to a cyclodextrin solution or a solution of cyclodextrin derivative and sonicate for 10-120 min; 5) directly add it to the cyclodextrin powder or the powder of cyclodextrin derivative and grind for 10-120 min; or 6) add the composition of ginsenoside Rg3 and ginsenoside Rg5 to the cyclodextrin powder or the powder of cyclodextrin derivative, mix well and sieve.

TABLE-US-00004 TABLE 4 Raw Material Ratio and Preparation Method of Exemplary Embodiments 181-198 Exemplary Weight of composition (g, content) □-Amount of Embodiment No. (Ginsenoside Rg3:ginsenoside Rg5) cyclodextrin in gram Preparation method Exemplary 100 (98.1%)(2:98) 100 1) Add directly embodiment 181 Exemplary 100 (98.1%)(2:98) 10000 2) Stir for 1 h embodiment 182 Exemplary 100 (98.1%)(2:98) 500 3) Heat for 10 min embodiment 183 Exemplary 100 (98.1%)(2:98) 1000 4) Sonicate for 10 min embodiment 184 Exemplary 100 (98.1%)(2:98) 2000 5) Grind for 10 min embodiment 185 Exemplary 100 (98.1%)(2:98) 3000 6) Mix well and sieve for embodiment 186 10 min Exemplary 100 (98.1%)(2:98) 4000 1) Add directly embodiment 187 Exemplary 100 (98.1%)(2:98) 3500 2) Stir for 12 h embodiment 188 Exemplary 100 (98.1%)(2:98) 4500 3) Heat for 120 min embodiment 189 Exemplary 100 (98.1%)(2:98) 1500 4) Sonicate for 120 min embodiment 190 Exemplary 100 (10.7%)(1:99) 100 1) Add directly embodiment 191 Exemplary 100 (10.7%)(1:99) 10000 2) Stir for 1 h embodiment 192 Exemplary 100 (10.7%)(1:99) 500 3) Heat for 10 min embodiment 193 Exemplary 100 (10.7%)(1:99) 1000 4) Sonicate for 10 min embodiment 194 Exemplary 100 (2.3%)(99:1) 100 1) Add directly embodiment 195 Exemplary 100 (2.3%)(99:1) 10000 2) Stir for 1 h embodiment 196 Exemplary 100 (2.3%)(99:1) 500 3) Heat for 10 min embodiment 197 Exemplary 100 (2.3%)(99:1) 1000 4) Sonicate for 10 min embodiment 198

[0058] The excipients in Exemplary Embodiment 181-198 are exemplified with selected-cyclodextrins, and other cyclodextrins and cyclodextrin derivatives are suitable for use in the present invention. Examples include 1) □-hydroxypropyl cyclodextrin, 2) hydroxyethyl-□-cyclodextrin, 3) 2,6-dimethyl-□-cyclodextrin, 4) 2,3,6-trimethyl-□-cyclodextrin, 5) 2,6-diethyl-□-cyclodextrin, 6) 2,3,6-triethyl-□-cyclodextrin, 7) maltosyl-□-cyclodextrin, 8) sulfobutylether β-cyclodextrin, 9) p-toluenesulfonyl chloride (p-TsCl) substituted β-cyclodextrin, 10) 6-position substituted β-CD p-toluenesulfonate (β-cyclodextrin-6-OTs), 11) 2-oxohydroxypropyl-β-cyclodextrin, 12) 2-position monosubstituted p-toluenesulfonate (2-β-cyclodextrin-2-OTs), 13) β-cyclodextrin p-toluenesulfonate (tosyl-β-CD) and 14) PCL-(Tos) 7-β-CD, the star-shaped macromolecule of β-cyclodextrin.

EXEMPLARY EMBODIMENT 199

Preparation of Tablets of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0059] Prepare the tablets of composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00005 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both 500 g in a weight ratio of 2:98) Starch 480 g Talc 1%(10 g) Magnesium stearate 1%(10 g)

[0060] Take appropriate amounts of the composition of ginsenoside Rg3 and ginsenoside Rg5 prepared by the process route in Exemplary Embodiments 1-180, add it with starch by the above ratios, mix well and prepare the mixture into granules, then add talc and magnesium stearate, mix well, and then compress the mixture into 0,000 tablets.

EXEMPLARY EMBODIMENT 200

Preparation of Granules of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0061] Prepare the granules of the composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00006 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both 100 g in a weight ratio of 98:2) Microcrystalline cellulose 10000 g 

[0062] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5 prepared by the process route in Exemplary Embodiments 1-180, add it with microcrystalline cellulose by the above ratios, mix well and prepare the mixture into granules and dispense into 10,000 sachets.

EXEMPLARY EMBODIMENT 201

Preparation of Capsules of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0063] Prepare the capsules of the composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00007 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both in 250 g a weight ratio of 2:98) Starch 2500 g 

[0064] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5 prepared by the process route in Exemplary Embodiments 1-180, add it with starch by the above ratios, mix well and dispense into 10,000 capsules.

EXEMPLARY EMBODIMENTS 202-205

Preparation of Capsules of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0065] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with starch according to the weight ratios in Table 5, mix well and then dispense it into 10,000 capsules.

TABLE-US-00008 TABLE 5 Raw Material Ratio of Exemplary Embodiments 202-205 Weight of composition Weight (g) (Ginsenoside ratio of Exemplary Rg3:ginsenoside Excipient raw material Embodiment No. Rg5) (Starch, g) to excipient Exemplary 500 (2:98)  500 1:1  embodiment 202 Exemplary  50 (10:90) 5000  1:100 embodiment 203 Exemplary 250 (25:75) 2500 1:10 embodiment 204 Exemplary 250 (50:50) 5000 1:20 embodiment 205

[0066] The raw materials described in the table can be the composition of ginsenoside Rg3 and ginsenoside Rg5 in the Exemplary Embodiments 1-180

EXEMPLARY EMBODIMENT 206-209

Preparation of Granules of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0067] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with microcrystalline cellulose according to the weight ratios described in Table 6, mix well and prepare it into granules, then dispense it into 10,000 sachets.

TABLE-US-00009 TABLE 6 Raw Material Ratios of Exemplary Embodiments 206-209 Weight of composition Excipient Weight (g) (Ginsenoside (Micro- ratio of Exemplary Rg3:ginsenoside crystalline raw material Embodiment No. Rg5) cellulose, g) to excipient Exemplary 1000 (2:98)  1000 1:1  embodiment 206 Exemplary  250 (10:90) 25000  1:100 embodiment 207 Exemplary 2500 (25:75) 25000 1:10 embodiment 208 Exemplary 2500 (50:50) 50000 1:20 embodiment 209

[0068] The raw materials described in the table can be the composition of ginsenoside Rg3 and ginsenoside Rg5 in the Exemplary Embodiments 1-180

EXEMPLARY EMBODIMENT 210

Preparation of Tablets of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0069] Prepare the tablets of composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00010 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both 500 g in a weight ratio of 98:2) Starch 380 g Licorice extract 100 g Talc 1%(10 g) Magnesium stearate 1%(10 g)

[0070] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with starch by the above ratios, mix well and prepare the mixture into granules, then add talc and magnesium stearate, mix well, and then compress the mixture into 10,000 tablets. Wherein, the composition of ginsenoside Rg3 and ginsenoside Rg5 in this exemplary embodiment can be substituted by the composition of ginsenoside Rg3 and ginsenoside Rg5 in Exemplary Embodiment 1-180.

EXEMPLARY EMBODIMENT 211

Preparation of Granules of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0071] Prepare the granules of the composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00011 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both 250 g in a weight ratio of 2:98) Licorice extract 250 g Microcrystalline cellulose 24500 g 

[0072] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with the above said extract powder by the above ratios, mix well and add it with microcrystalline cellulose and mix well; and then prepare the mixture into granules and dispense into 10,000 sachets. Wherein, the composition of ginsenoside Rg3 and ginsenoside Rg5 in this exemplary embodiment can be substituted by the composition of ginsenoside Rg3 and ginsenoside Rg5 in Exemplary Embodiment 1-180.

EXEMPLARY EMBODIMENT 212

Preparation of Capsules of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0073] Prepare the capsules of the composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00012 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both in 250 g a weight ratio of 2:98) Licorice extract 250 g Extract of fritillariae cirrhosae bulbus 250 g Extract of folium llicis latifoliae 250 g Starch 1000 g 

[0074] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with the above said extract powder, mix well and add it with starch and mix well; and then dispense into 10,000 capsules. Wherein, the composition of ginsenoside Rg3 and ginsenoside Rg5 in this exemplary embodiment can be substituted by the composition of ginsenoside Rg3 and ginsenoside Rg5 in Exemplary Embodiment 1-180.

EXEMPLARY EMBODIMENT 213

Preparation of Tablets of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0075] Prepare the tablets of composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00013 Composition of ginsenoside Rg3 and ginsenoside Rg5 (both in 500 g a weight ratio of 2:98) Starch 480 g Extract of anemarrhenae rhizoma 500 g Talc 1%(10 g) Magnesium stearate 1%(10 g)

[0076] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with the above said extract powder by the above ratios, mix well and add starch and mix well and prepare the mixture into granules, then add talc and magnesium stearate, mix well, and then compress the mixture into 10,000 tablets. Wherein, the composition of ginsenoside Rg3 and ginsenoside Rg5 in this exemplary embodiment can be substituted by the composition of ginsenoside Rg3 and ginsenoside Rg5 prepared in Exemplary Embodiment 1-180.

EXEMPLARY EMBODIMENT 214

Preparation of Granules of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0077] Prepare the granules of the composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00014 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both 1000 g  in a weight ratio of 10:90) Extract of scrophulariae radix 500 g Extract lophatherum gracile 500 g Microcrystalline cellulose 10000 g 

[0078] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with the above said extract powder by the above ratios, mix well and add it with microcrystalline cellulose and mix well; and then prepare the mixture into granules and dispense into 10,000 sachets. Wherein, the composition of ginsenoside Rg3 and ginsenoside Rg5 in this exemplary embodiment can be substituted by the composition of ginsenoside Rg3 and ginsenoside Rg5 prepared in Exemplary Embodiment 1-180.

EXEMPLARY EMBODIMENT 215

Preparation of Solid Beverage of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0079] Prepare the solid beverage of the composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00015 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both in 1000 g a weight ratio of 10:90) Powdered sugar 5000 g

[0080] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with the above said extract powder, mix well and then prepare the mixture into granules and dispense into 10,000 sachets. Wherein, the composition of ginsenoside Rg3 and ginsenoside Rg5 in this exemplary embodiment can be substituted by the composition of ginsenoside Rg3 and ginsenoside Rg5 prepared in Exemplary Embodiment 1-180.

EXEMPLARY EMBODIMENT 216

Preparation of Compressed Confectionery Tablets of Composition of Ginsenoside Rg3 and Ginsenoside Rg5

[0081] Prepare the solid beverage of the composition of ginsenoside Rg3 and ginsenoside Rg5 according to the following ratios:

TABLE-US-00016 A composition of ginsenoside Rg3 and ginsenoside Rg5 (both in 1000 g a weight ratio of 10:90) Powdered sugar 5000 g

[0082] Take an appropriate amount of the composition of ginsenoside Rg3 and ginsenoside Rg5, add it with the above said extract powder, mix well and prepare it into granules and compress into tablets, then prepare 10,000 tablets. Wherein, the composition of ginsenoside Rg3 and ginsenoside Rg5 in this exemplary embodiment can be substituted by the composition of ginsenoside Rg3 and ginsenoside Rg5 prepared in Exemplary Embodiment 1-180.

[0083] Exemplary Test 1 Immunity Boosting Effect of Ginsenoside Rg3 and Ginsenoside Rg5 in Mice

[0084] 1. Experimental Materials

[0085] 1.1 Drugs and Reagents

[0086] The composition of ginsenoside Rg3 and ginsenoside Rg5 is produced by Dalian Fusheng Natural Drugs Development Co., Ltd. The contents of Rg3 and Rg5 were determined by HPLC, respectively. See Table 7 for details.

TABLE-US-00017 TABLE 7 List of Compositions Used in Exemplary Test 1 Content of Rg3 Proportion of each component Composition and Rg5 in the in the composition Serial No. composition s-Rg3 R-Rg3 Rg5 A 98.1% 1 98 1 B 2.2% 1 1 98 C 11.6% 98 1 1 D 98.0% 98 1 1 E 2.4% 1 98 1 F 10.7% 1 98 1 G 98.3% 1 1 98 H 2.3% 98 1 1 I 10.1% 1 1 98 Positive control drug: Pidotimod Oral Solution (Suzhou Pharmaceutical Factory of Jiangsu Wuzhong Pharmaceutical Group Corporation, strength: 10 ml/400 mg, lot No.: 2014091211)

[0087] 1.2 Experimental Animals

[0088] Kunming mice, aged 6-8 weeks, weighing 18-22 g, were purchased from Experimental Animal Center of Dalian Medical University, with the quality certificate No.: SCXK (13) 2013-0003.

[0089] 2. Experimental Method

[0090] 2.1 Grouping and Administration

[0091] A total of 290 healthy male mice, as mentioned above, were subjected to acclimation for 4 days before they were randomly divided into 29 groups according to body weight, including the negative control group, the positive control group and ginsenoside composition experimental group, and the animals in the latter group were further divided into high dose group, medium dose group and low dose group, respectively. The animals of the positive control group were given pidotimod (50 mg/kg), those in the low dose ginsenoside composition group were given low dose ginsenoside composition (36 mg/kg), those in the medium dose group were given medium dose ginsenoside composition (72 mg/kg), those in the high dose group were given high dose of ginsenoside composition (144 mg/kg) and those in the negative control group were given the same volume of water. Drugs and water were administered once daily for 30 consecutive days.

[0092] 2.2 Experiments and Results

[0093] 2.2.1 ConA-Induced Mouse Splenic Lymphocyte Transformation Test

[0094] At 1 h after the last dose, the spleens of animals of each group were aseptically excised to prepare splenocyte suspension. After diluting the splenocyte suspension to a concentration of 3×10.sup.6 cells/mL, the splenocyte suspension was divided into 2 aliquots. Each of the aliquot was transferred into two 24-well culture plates, respectively at a volume of 1 mL/well, and then 75 μL ConA solution (a) was added to a well, and the other well was used as control (b), which were cultured at 37° C. for 72 h. Thiazolyl blue (MTT) was added 4 h before the end of the culture. After incubation, acidic isopropanol was added, and the absorbance (ABS) of each solution was measured at 570 nm after mixing well. The proliferativity was calculated using the formula (proliferativity=ABSa-ABSb). Each dose group of the test sample was compared with the negative control group. The experimental results are shown in Table 1.

[0095] 2.2.2 Determination of NK Cell Viability

[0096] At 1 h after the last dose, the spleens of animals of each group were aseptically excised to prepare splenocyte suspension. After the red blood cells were lysed with sterile water for injection, the cell suspension was diluted with 1% glacial acetic acid. Then, after adjusting the concentration of splenocyte suspension to 2×10.sup.7 cells/mL, the splenocyte suspension was added to a 96-well plate for culturing. For each animal, the wells were divided into reaction wells (splenocyte suspension and YAC-1 cell suspension 100 μL each; effector-to-target ratio was 50:1); natural release wells (YAC-1 cell suspension and culture medium 100 μL each) and maximum release wells (YAC-1 cell suspension and 1% NP40 100 μL each). A triplicate set of tubes was prepared for each of the above items. The 96-well plate was incubated at 37° C. in a 5% CO.sub.2 incubator for 4 h. then, after addition of LDH matrix solution and 1 moL/LHC1, the solutions in each parallel well were combined, and the absorbance (ABS) was measured at 490 nm. Then, the NK cell viability was calculated. NK cell viability (%)=(ABS.sub.reaction well−ABS.sub.natural release well)/(ABS.sub.maximum release well−ABS.sub.natural release well). The experimental results are shown in Table 8.

TABLE-US-00018 TABLE 8 Effect of Ginsenoside Composition on NK Cell Viability and ConA-induced Lymphocyte Proliferation Ability (x ± s) Dose admin- NK cell Proliferation istered viability ability Group (mg/kg) (%) (×10.sup.−2) Negative control group — 34.14 ± 5.68  9.04 ± 3.81 Positive control group 50 42.57 ± 7.31  27.97 ± 11.45 Compo- Low dose group 36 64.14 ± 5.40 44.27 ± 5.52 sition A Medium dose group 72 70.04 ± 8.32 50.14 ± 9.59 High dose group 144 76.53 ± 7.33  58.69 ± 11.23 Compo- Low dose group 36 75.55 ± 9.15 27.99 ± 8.03 sition B Medium dose group 72  48.53 ± 10.53  28.61 ± 10.12 High dose group 144 51.73 ± 8.76  31.99 ± 16.87 Compo- Low dose group 36 53.56 ± 6.84  33.94 ± 10.60 sition C Medium dose group 72 55.82 ± 6.29  35.44 ± 11.74 High dose group 144  57.54 ± 11.97  37.64 ± 13.61 Compo- Low dose group 36 64.78 ± 5.40 44.32 ± 6.22 sition D Medium dose group 72  70.54 ± 10.24 50.02 ± 5.24 High dose group 144 76.84 ± 9.33 58.51 ± 4.98 Compo- Low dose group 36 45.78 ± 9.15 27.95 ± 7.99 sition E Medium dose group 72  47.45 ± 10.53 27.33 ± 9.28 High dose group 144 50.94 ± 8.47 30.52 ± 7.53 Compo- Low dose group 36 53.78 ± 6.84 33.64 ± 8.57 sition F Medium dose group 72  55.49 ± 11.29  35.46 ± 10.68 High dose group 144 57.65 ± 7.97 37.48 ± 9.24 Compo- Low dose group 36 65.77 ± 5.40 45.68 ± 8.57 sition G Medium dose group 72 71.65 ± 8.32 51.71 ± 8.53 High dose group 144 77.95 ± 7.38 59.61 ± 8.64 Compo- Low dose group 36 43.88 ± 9.15 27.35 ± 9.63 sition H Medium dose group 72 47.45 ± 9.01 28.96 ± 8.59 High dose group 144 50.46 ± 5.37 30.57 ± 9.85 Compo- Low dose group 36 54.14 ± 8.44 34.94 ± 6.87 sition I Medium dose group 72  56.95 ± 11.29  36.08 ± 10.68 High dose group 144 58.74 ± 7.97  38.84 ± 12.60

[0097] 3. Test Results

[0098] Following the stimulation of T lymphocytes by ConA, the blast cells will show proliferative responses. The mitochondrial hydrolase in the viable cells, especially the proliferating cells, decomposes MTT into blue-purple crystals. If the optical density value is increased, it indicates that the cell proliferation ability is enhanced. As shown in Table 1, the optical density differences of the high-, medium- and low-dose groups of the ginsenoside composition were higher than those of the negative control group, indicating that this sample can promote the proliferation of splenocytes.

[0099] After the cells are killed by the NK cells, the LDH in the cytoplasm of viable cells will be released to the outside of the cells, and LDH can dehydrogenate lithium lactate, so that NAD is reduced to NADH, which in turn is reduced to iodonitro-tetrazolium chloride (INT) through hydrogen transmitter phenazine methosulfate (PMS). After receiving H+, the INT is reduced to a purple formazan compound and the optical density value is determined using a microplate reader. As shown in Table 1, the NK cell viability of the high-, medium- and low-dose groups of the ginsenoside composition was significantly higher than that of the negative control group, indicating that the sample can increase the viability of the NK cells.

[0100] The above experimental results showed that all the different doses of the composition of ginsenoside Rg3 and ginsenoside Rg5 could promote the proliferation of splenocytes, increase the viability of the NK cells, and could significantly improve the immune function.

[0101] Exemplary Test 2 Anti-tumor Effect of Ginsenoside Composition on S180 Sarcoma in Mice

[0102] 1. Experimental Materials

[0103] 1.1 Experimental Animals and Transplanted Tumor Strains

[0104] Kunming mice, provided by Guangdong Medical Laboratory Animal Center, with certificate No.: SCXK2013-005;

[0105] S180 sarcoma cells, purchased from Guangdong Medical Laboratory Animal Center.

[0106] 1.2 Drug Product

[0107] The composition of ginsenoside Rg3 and ginsenoside Rg5 is produced by Dalian Fusheng Natural Drugs Development Co., Ltd. The contents of Rg3 and Rg5 were determined by HPLC, respectively.

TABLE-US-00019 TABLE 9 List of Compositions Used in Exemplary Test 2 Content of Rg3 Proportion of each component Composition and Rg5 in the in the composition Serial No. composition s-Rg3 R-Rg3 Rg5 A 98.1% 1 98 1 B 2.2% 1 1 98 C 11.6% 98 1 1 D 98.0% 98 1 1 E 2.4% 1 98 1 F 10.7% 1 98 1 G 98.3% 1 1 98 H 2.3% 98 1 1 I 10.1% 1 1 98

[0108] The low, medium and high doses of the investigational product were 2 times, 4 times and 8 times the clinical equivalent dose for adults (calculated according to the body weight of 60 kg of adults), respectively. The suspension at the required concentration was prepared with double distilled water. The prepared drug solution was stored in a refrigerator at 4° C. and protected from light until use.

[0109] The positive control drug is cyclophosphamide (lot No.: 20130105, Jiangsu Hengrui Medicine Co., Ltd.). For the clinical equivalent dose for the adults (calculated according to the body weight of 60 kg of adults), the required suspension was prepared with double distilled water and stored in a refrigerator at 4° C. and protected from light until use.

[0110] 2. Experimental Method

[0111] 2.1 Grouping and Administration

[0112] Mice inoculated with sarcoma 180 (S180) ascites tumor cells which were well grown for 7 days were taken and the ascities fluid was aseptically collected, then diluted with sterile normal saline to adjust the cell number to 2×10.sup.6/0.2 mL and stored in ice water until use.

[0113] A total of 300 healthy Kunming mice (half male and half female) aged 6-8 weeks and weighing 18-22 g were preliminarily housed for 1 week under the experimental conditions. After that, 10 of the animals were randomly selected as the blank control group, and the remaining 290 mice were subcutaneously inoculated with 0.2 mL of S180 tumor cell suspension in the axilla of the left hind limb of each mouse. Twenty-four hours following the inoculation, the mice were weighed and randomly divided into 29 groups, i.e., the tumor-bearing control group, positive control group and ginsenoside composition experimental group. And the animals in the latter group were further divided into the high dose groups, medium dose groups and low dose groups, respectively. Starting from the grouping day, animals in the low dose group (36 mg/kg), medium dose group (72 mg/kg) and high dose group (144 mg/kg) of the ginsenosides composition and the positive control group were administered with cyclophosphamide 45 mg/kg via oral gavage Animals in the normal control group and the model group were given equivalent amount of normal saline via oral gavage once daily.

[0114] After modeling and medication, the food intake, water intake, changes in coat color, activity, response to stimulation, presence of diarrhea, emaciation and death of mice in each group were observed and recorded at any time. Drugs were discontinued on the 21.sup.st day after oral gavage administration. On the next day, the mice were sacrificed by cervical dislocation and weighed. The subcutaneous tumor tissues of the left hind limb were completely stripped and weighed using an electronic balance after removing all the non-tumor tissues, such as blood stain and fat. The tumor inhibition rate was calculated according to the following formula:

Tumor inhibition rate=(average tumor weight of control group-average tumor weight of treatment group)/average tumor weight of control group×100%

[0115] 2.2 The data were expressed as mean±standard deviation (±s). The inter-group comparison of the measurement data was subjected to one-way analysis of variance using SPASS 13.0 statistical software. p<0.05 indicates statistically significant differences.

[0116] 3. Experimental Results

[0117] 3.1 Observation of General Conditions of Animals after Administration

[0118] After administration, the mice in all the groups were alive; the mice in the blank control group had normal food and water intake, flexible movement, quick reaction, shiny hair coat, and had no diarrhea or emaciation. In comparison, the general condition of the mice in each dose group of ginsenoside composition was inferior to those of the blank control group. Mice in the positive control group had poor food and water intake, slow movement, slow reaction, shedding and dull hair coat color, diarrhea and emaciation. The general conditions of the mice in the tumor-bearing control group were the worst, with little food intake and activity, slow reaction, haggard hair coat, and obvious emaciation.

[0119] 3.2 The weight of transplanted tumors and tumor inhibition rates of the mice in each group are shown in Table 10.

TABLE-US-00020 TABLE 10 Weight of Transplanted Tumors and Tumor Inhibition Rates of Mice in Each Group Number of Weight of Tumor Dose animals transplanted inhibition mg/ (animal) tumor rate Group kg/d Start/End (g) ± S % Blank control — 10/10 — — Tumor-bearing control — 10/10 3.66 ± 0.59 — Positive control group 45 10/10 2.45 ± 0.62 33.06 Ginsenoside Low dose 36 10/10 1.76 ± 084. 51.91 composition group A Medium 72 10/10 1.57 ± 0.62 57.1 dose group High dose 144 10/10 1.21 ± 1.54 66.94 group Ginsenoside Low dose 36 10/10 2.48 ± 0.64 32.24 composition group B Medium 72 10/10 2.36 ± 1.31 35.52 dose group High dose 144 10/10 2.26 ± 0.81 38.25 group Ginsenoside Low dose 36 10/10 2.15 ± 0.89 41.25 composition group C Medium 72 10/10 2.06 ± 0.98 43.72 dose group High dose 144 10/10 1.99 ± 1.04 45.63 group Ginsenoside Low dose 36 10/10 1.77 ± 0.69 51.64 composition group D Medium 72 10/10 1.61 ± 1.06 56.01 dose group High dose 144 10/10 1.24 ± 1.09 66.12 group Ginsenoside Low dose 36 10/10 2.52 ± 0.57 31.15 composition group E Medium 72 10/10 2.39 ± 0.68 34.70 dose group High dose 144 10/10 2.29 ± 1.69 37.43 group Ginsenoside Low dose 36 10/10 2.14 ± 0.97 41.53 composition group F Medium 72 10/10 2.09 ± 0.86 42.90 dose group High dose 144 10/10 2.00 ± 1.24 45.36 group Ginsenoside Low dose 36 10/10 1.72 ± 0.76 53.00 composition group G Medium 72 10/10 1.55 ± 0.81 57.65 dose group High dose 144 10/10 1.24 ± 0.67 66.12 group Ginsenoside Low dose 36 10/10 2.50 ± 0.65 31.69 Combination group H Medium 72 10/10 2.39 ± 1.21 34.70 dose group High dose 144 10/10 2.29 ± 0.59 37.43 group Ginsenoside Low dose 36 10/10 2.15 ± 0.54 41.26 composition group I Medium 72 10/10 2.08 ± 0.58 43.17 dose group High dose 144 10/10 1.98 ± 0.89 45.90 group

[0120] The experimental results showed that the weight of transplanted tumors in mice of the treatment group was significantly lower than those in the control group, indicating that the ginsenoside compositions A, B, C had an anti-tumor effect on transplanted S180 sarcoma in mice, and the tumor inhibition rates of ginsenoside compositions A, D, G were greater than 50%, which sufficiently indicated that the ginsenoside compositions had prominent tumor inhibiting effect.

[0121] Exemplary Test 3: Ginsenoside Composition Improves Resistance to Anti-tumor Targeted Drugs

[0122] 1. Materials and Methods Human cholangiocarcinoma cell line QBC939, purchased from Shanghai Honshun Biological Technology Co., Ltd.

[0123] For the ginsenoside composition produced by Dalian Fusheng Natural Drugs Development Co., Ltd., see Table 11 for details.

TABLE-US-00021 TABLE 11 List of Compositions Used in Exemplary Test 3 Content of Rg3 Proportion of each component Composition and Rg5 in the in the composition Serial No. composition s-Rg3 R-Rg3 Rg5 A 98.1% 1 98 1 B 2.2% 1 1 98 C 11.6% 98 1 1 D 98.0% 98 1 1 E 2.4% 1 98 1 F 10.7% 1 98 1 G 98.3% 1 1 98 H 2.3% 98 1 1 I 10.1% 1 1 98

[0124] 2. Experimental Method

[0125] 2.1 Construction of Drug-Resistant Cancer Cell Lines

[0126] The human cholangiocarcinoma cell line QBC939 was thawed and inoculated into T25 cell culture flasks filled with cell culture medium, and QBC939/ADM was constructed by continuously increasing the contact concentration of ADM.

[0127] 2.2 CCK-8 Assay in Detecting Cytotoxicity of Chemotherapeutic Agents

[0128] The cells were divided into a blank zeroed control group, a normal control group and 9 experimental groups, each containing 100 μL of 80 μg/mL ginsenoside composition for cell culturing.

[0129] The control group (chemotherapeutic drug group): 100 μL of culture medium containing chemotherapeutic drugs was added to each well. The chemotherapeutic drugs included the targeted drugs afatinib (400 μg/mL), ceritinib (1000 μg/mL) and erlotinib (200 μg/mL). Six replicate wells were set up for each drug.

[0130] The experimental group (chemotherapeutic drugs+traditional Chinese medicine): 100 μL of culture medium containing chemotherapeutic drugs+ginsenoside composition was added to each well, namely afatinib (400 μg/mL)+ginsenoside composition (80 μg/mL), ceritinib (1000 μg/mL)+ginsenoside composition (80 μg/mL), and erlotinib (200 μg/mL)+ginsenoside composition (80 μg/mL). Six replicate wells were set up for each drug.

[0131] 3. Experimental Results

[0132] The cytotoxic effects of the chemotherapeutic drugs were detected 24 h later. The results showed that the OD value (absorbance) of the cells in the experimental group was significantly lower than that in the control group, indicating that the viability of the cells in the experimental group was significantly lower than that in the control group, and the cytotoxic effect of the chemotherapeutic drugs on the cells in the experimental group was significantly more potent than that in the control group, indicating that the ginsenoside composition experimental group had the effect of reversing drug resistance. The results are shown in Table 12.

TABLE-US-00022 TABLE 12 Absorbance Values in Drug Resistance Test Group Afatinib Ceritinib Erlotinib Control group 1.179 ± 0.147 1.304 ± 0.096 1.294 ± 0.131 Composition A 0.703 ± 0.132 0.611 ± 0.101 0.608 ± 0.122 Composition B 1.002 ± 0.102 0.924 ± 0.122 0.913 ± 0.135 Composition C 0.950 ± 0.141 0.840 ± 0.139 0.837 ± 0.095 Composition D 0.706 ± 0.127 0.613 ± 0.092 0.604 ± 0.134 Composition E 1.016 ± 0.135 0.914 ± 0.137 0.902 ± 0.127 Composition F 0.943 ± 0.129 0.856 ± 0.121 0.844 ± 0.131 Composition G 0.691 ± 0.136 0.573 ± 0.126 0.562 ± 0.134 Composition H 1.013 ± 0.097 0.930 ± 0.127 0.823 ± 0.098 Composition I 0.941 ± 0.087 0.852 ± 0.093 0.841 ± 0.096

[0133] Exemplary Test 4: Experiment of Ginsenoside Composition in Relieving Side Effects (Vomiting) of Radiotherapy and Chemotherapy

[0134] 1. Experimental Materials

[0135] 1.1 Drugs and Reagents:

[0136] The ginsenoside composition is white to brownish yellow powder manufactured by Dalian Fusheng Natural Drugs Development Co., Ltd. Its content was determined by high performance liquid chromatography (HPLC) with two kinds of detectors and UV detector and using the reference standard of National Institute for the Control of Pharmaceutical and Biological Products as the external standard. See Table 13 for details.

TABLE-US-00023 TABLE 13 List of Compositions Used in Exemplary Test 4 Content of Rg3 Proportion of each component Composition and Rg5 in the in the composition Serial No. composition s-Rg3 R-Rg3 Rg5 A 98.1% 1 98 1 B 2.2% 1 1 98 C 11.6% 98 1 1 D 98.0% 98 1 1 E 2.4% 1 98 1 F 10.7% 1 98 1 G 98.3% 1 1 98 H 2.3% 98 1 1 I 10.1% 1 1 98

[0137] Positive control drug: metoclopramide Injection (Tianjin Renmin Pharmaceutical Factory, strength: 1 mL/10 mg, lot No.: 14060129);

[0138] Kaolin (Shanghai Fengxian Fengcheng Reagent Factory, lot No.: 1140528);

[0139] Preparation of kaolin for rats: 1 g of acacia gum was weighed and added with 100 mL of distilled water, then it was placed on a magnetic stirrer and stirred until completely dissolved; then an appropriate amount of kaolin which has been sieved through a 80 mesh sieve was taken and slowly added into the above solution while stirring, allowing it to form into a dough-like shape. Then, it was squeezed into a 5 mL syringe until the syringe was completely filled; then the plunger rod was pushed to prepare small rods with very smooth edges with the shape resembling that of normal foods; then the rods were placed into a dryer filled with blue silica gel particles and allowed to dry for later use.

[0140] 1.2 Experimental Animals:

[0141] Male Wistar rats, weighing 200-220 g, were purchased from the Experimental Animal Center of Dalian Medical University, with quality certificate No.: SCXK (13) 2013-0002.

[0142] 2. Experimental Method

[0143] Rats are rodents with no vomiting reactions. The pica behavior of rats after vestibular stimulation is equivalent to the reaction of vomiting of other animals, which can be regarded as a typical symptom of motion sickness in rats.

[0144] 2-1. Breeding of Rats for Acclimation

[0145] Before the initiation of the experiment, the rats were bred for acclimation, that is, the quantified routine feeds and kaolin feed were given to the rats simultaneously. Two kinds of feeds were taken out and weighed at regular time points every day to observe bite marks on the feed surface until the rats almost no longer gnawed the kaolin, and then the formal experiment was started.

[0146] 2-2 Pica Test

[0147] Wistar rats were randomly divided into 29 groups (with 6 rats in each group), namely the model control group, the positive drug control group, the ginsenoside composition experimental group and the last group was further divided into three groups, i.e., the low-, medium- and high-dose groups.

[0148] The rats in the model control group were given saline at 10 mL/kg via oral gavage; those in the positive control group were intraperitoneally injected with metoclopramide at 2 mg/kg; and those in the low-, medium- and high-dose groups of ginsenoside composition were administered with ginsenoside compositions A-I at 15 mg/kg, 30 mg/kg and 60 mg/kg, respectively.

[0149] At 30 min post-dose, rotatory stimulation was applied using the rotatory stimulation device modified from a centrifuge to induce motion sickness, with the rotatory speed of 100 rotations/min and rotate for 1 h.

[0150] The rats of each group were observed for the kaolin ingestion pica behavior and the consumption of routine diet and kaolin was recorded within 24 h after the rotatory stimulation was stopped.

[0151] 3. Test Results

[0152] All the data were expressed as mean±standard deviation (X±S), and the PPMS medical statistical software was used for the analysis of variance and the significance test by comparing the P values. The statistical results of the consumption of routine diet and kaolin are shown in Table 14.

TABLE-US-00024 TABLE 14 Effect of Ginsenoside Compositions on Rotation-induced Pica Behavior in Rats (X ± s, n = 6) Group Kaolin intake (g) Food intake (g) Blank control group 0.601 ± 0.097 12.96 ± 1.03 Positive control group 0.404 ± 0.131 23.97 ± 1.16 Ginsenoside Low dose group 0.347 ± 0.073 22.13 ± 1.67 composition Medium dose group 0.321 ± 0.101 24.96 ± 1.90 A High dose group 0.314 ± 0.042 26.92 ± 1.52 Ginsenoside Low dose group 0.473 ± 0.064 14.29 ± 1.36 composition Medium dose group 0.439 ± 0.093 15.37 ± 1.91 B High dose group 0.413 ± 0.065 16.48 ± 0.93 Ginsenoside Low dose group 0.381 ± 0.082 17.13 ± 2.71 composition Medium dose group 0.369 ± 0.094 18.52 ± 1.94 C High dose group 0.362 ± 0.113 20.67 ± 0.99 Ginsenoside Low dose group 0.347 ± 0.072 22.43 ± 1.63 composition Medium dose group 0.319 ± 0.061 25.32 ± 1.84 D High dose group 0.310 ± 0.057 26.67 ± 1.57 Ginsenoside Low dose group 0.464 ± 0.119 14.03 ± 1.73 composition Medium dose group 0.428 ± 0.070 15.88 ± 0.91 E High dose group 0.415 ± 0.054 16.93 ± 1.22 Ginsenoside Low dose group 0.384 ± 0.077 17.81 ± 1.53 composition Medium dose group 0.377 ± 0.113 18.59 ± 1.04 F High dose group 0.365 ± 0.085 20.14 ± 1.01 Ginsenoside Low dose group 0.346 ± 0.090 22.38 ± 1.73 composition Medium dose group 0.325 ± 0.041 25.52 ± 1.86 G High dose group 0.318 ± 0.086 26.27 ± 1.42 Ginsenoside Low dose group 0.469 ± 0.044 14.63 ± 1.27 composition Medium dose group 0.435 ± 0.082 15.27 ± 0.84 H High dose group 0.410 ± 0.059 16.84 ± 1.27 Ginsenoside Low dose group 0.383 ± 0.105 17.35 ± 1.65 composition Medium dose group 0.379 ± 0.064 19.46 ± 1.21 I High dose group 0.360 ± 0.097 20.74 ± 0.98

[0153] The experimental results showed that:

[0154] The main side effect of radiotherapy and chemotherapy was vomiting, which was reflected in the pica behavior of kaolin ingestion of the rats. In each of the ginsenoside composition dose group, the pica behavior of kaolin ingestion of the rats was significantly inhibited, and the amount of kaolin intake was significantly decreased compared with the blank control group (P<0.05, P<0.01). In each dose group of the ginsenoside composition, the treatment could significantly increase the food intake of the rats. The results of the above experiments showed that ginsenoside composition has a significant effect in alleviating emesis caused by radiotherapy and chemotherapy. Hence, the composition has good prospects for clinical application.

[0155] Examplary Test 5: Anti-Fatigue Effect of Ginsenoside Composition

[0156] 1. Experimental Materials

[0157] 1.1 Drugs and Reagents

[0158] SOD Assay Kit, Jiancheng Biotechnology Co., Ltd.

[0159] The composition of ginsenoside Rg3 and ginsenoside Rg5, lot No.: 20120316, was produced by Dalian Fusheng Natural Drugs Development Co., Ltd. The contents of Rg3 and Rg5 were determined by HPLC, respectively, using the reference standard provided by the National Institute for the Control of Pharmaceutical and Biological Products.

TABLE-US-00025 TABLE 17 List of Compositions Used in Exemplary Test 6 Content of Rg3 Proportion of each component Composition and Rg5 in the in the composition Serial No. composition s-Rg3 R-Rg3 Rg5 A 98.1% 1 98 1 B 2.2% 1 1 98 C 11.6% 98 1 1 D 98.0% 98 1 1 E 2.4% 1 98 1 F 10.7% 1 98 1 G 98.3% 1 1 98 H 2.3% 98 1 1 I 10.1% 1 1 98

[0160] 1.2 Experimental Animals:

[0161] BALB/C nude mice, weighing 26-28 g, aged 6 weeks, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.

[0162] 2. Experimental Method

[0163] 2.1 Grouping and Administration:

[0164] A total of 280 selected male mice were firstly bred for 8 weeks, bred for acclimation for 1 week and then provided with exercise training for 1 week.

[0165] They were randomly divided into 28 groups according to body weight, including the control group and the ginsenoside composition experimental groups, and animals in the latter group were further divided into high dose group, medium dose group and low dose group, respectively.

[0166] Animals in the control group were given normal saline; those in the low dose ginsenoside composition group were given low dose of ginsenoside composition (3.2 mg/kg); those in the medium dose group were given medium dose of ginsenoside composition (6.4 mg/kg); and those in the high dose group were given high dose of ginsenoside composition (12.8 mg/kg). The drug was administered once daily for 30 consecutive days.

[0167] 2.3 Experiments and Results

[0168] Exhaustive Swimming Test

[0169] The dimension of the swimming pool is 185 cm×73 cm×58 cm, and it was 30 cm deep when the animals were swimming, and the water temperature was 27±1° C. Nude mice were put into the swimming pool, and the time interval from going into the water to swim to the time of exhaustion was recorded. The judgment standard for exhaustion is that the mice demonstrate obvious movement disorder, with the head sinking into the water and failing to rise above the water surface for 8 s.

[0170] Determination of SOD Activity

[0171] The activity of SOD in the blood is an important indicator of the body's anti-fatigue ability. It can be used to evaluate the fatigue index.

TABLE-US-00026 TABLE 18 Exhaustive Swimming Test and SOD Data Sheet Swimming SOD Group Dose (mg/kg) duration (s) activity (u/mL) Blank control — 91.21 ± 6.4  60.56 ± 6.4  group Composition A 12.8 119.0 ± 3.1  93.7 ± 4.1 6.4 113.4 ± 2.1  90.3 ± 5.9 3.2 106.2 ± 2.2  87.2 ± 4.3 Composition B 12.8 95.1 ± 5.3 75.7 ± 6.2 6.4 94.8 ± 2.7 74.6 ± 2.8 3.2 93.0 ± 3.4 73.4 ± 5.4 Composition C 12.8 101.3 ± 6.5  83.3 ± 6.3 6.4 98.2 ± 3.3 81.5 ± 4.7 3.2 96.5 ± 4.7 80.7 ± 5.5 Composition D 12.8 119.2 ± 3.6  93.8 ± 3.4 6.4 113.1 ± 4.1  90.4 ± 1.6 3.2 105.8 ± 5.9  87.7 ± 5.6 Composition E 12.8 95.7 ± 5.8 75.8 ± 6.5 6.4 94.4 ± 3.2 74.7 ± 3.5 3.2 93.9 ± 3.1 73.3 ± 5.7 Composition F 12.8 101.6 ± 5.0  83.5 ± 4.6 6.4 98.2 ± 3.4 81.7 ± 3.4 3.2 96.8 ± 3.1 80.3 ± 6.8 Composition G 12.8 119.9 ± 2.4  93.9 ± 5.7 6.4 113.6 ± 5.6  90.5 ± 5.3 3.2 106.4 ± 2.3  87.8 ± 3.9 Composition H 12.8 95.4 ± 4.5 75.7 ± 3.9 6.4 94.0 ± 4.8 74.6 ± 4.2 3.2 93.1 ± 4.5 73.6 ± 3.0 Composition I 12.8 101.6 ± 3.7  83.2 ± 5.8 6.4 98.2 ± 4.0 81.3 ± 4.1 3.2 96.5 ± 4.7 80.4 ± 3.1

[0172] The data in this table showed that the exhaustive swimming duration of the mice in the ginsenoside composition groups was significantly longer than that in the control group, and the SOD activity was significantly higher than that in the exhaustive swimming group with a significant difference, indicating that the ginsenoside composition has a prominent anti-fatigue effect.